Quick Answer
GUIDED THERAPEUTICS INC reported Diluted EPS of $0.04 per share (loss) for fiscal year 2025.
GUIDED THERAPEUTICS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.04 | +20.0% |
| 2024 | -$0.05 | +28.6% |
| 2023 | -$0.07 | +53.3% |
| 2022 | -$0.15 | +16.7% |
| 2021 | -$0.18 | -350.0% |
| 2020 | -$0.04 | +93.1% |
| 2019 | -$0.58 | -4302.9% |
| 2018 | $0.01 | — |
| 2017 | $0.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.01 | +0.0% | +0.0% |
| June 30, 2025 | -$0.01 | +0.0% | +0.0% |
| March 31, 2025 | -$0.01 | +0.0% | +0.0% |
| September 30, 2024 | -$0.01 | +0.0% | +0.0% |
| June 30, 2024 | -$0.01 | +66.7% | +0.0% |
| March 31, 2024 | -$0.01 | +50.0% | +0.0% |
| September 30, 2023 | -$0.01 | +66.7% | +66.7% |
| June 30, 2023 | -$0.03 | +25.0% | -50.0% |
- GUIDED THERAPEUTICS INC showed an increase of +20.0% in Diluted EPS compared to the prior fiscal year.
- The most recent figure is from GUIDED THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: